Entering text into the input field will update the search result below

Lilly's Tyvyt 'significantly improves' overall survival as a second-line treatment for lung cancer

  • Eli Lilly (NYSE:LLY) and Innovent Biologics (OTCPK:IVBIY) announce that the results of Phase 3 ORIENT-3 study evaluating Tyvyt (sintilimab injection) vs. docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) were released at AACR Meeting 2021.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
LLY
--
IVBIY
--